Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: COCRYSTAL PHARMA, INC.
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2025-09-29 to 2026-09-29
Current total value of award: $498199
Description: DEVELOPMENT OF PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX